2024年,礼来实现营收450亿美元,同比增长32%。其中,替尔泊肽(包括2型糖尿病和肥胖症适应症)实现营收165亿美元,占总营收的比重达37%,同比增长超过200%。然而,单品依赖难以走出长期稳健的发展路径。在围绕GLP-1的心血管代谢和肥胖症赛道之外,礼来正在布局新筹码:基因药物和核药。2月11日,礼来与OliX Pharmaceuticals公司达成合作协议,聚焦于用于治疗代谢性脂肪肝的一期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.